FDA.reportPublic FDA data

Palsonify 30 MG Oral Tablet

RxCUI
2724413
RxNorm name
Palsonify 30 MG Oral Tablet
Display name
Palsonify 30 MG Oral Tablet
Full name
Palsonify 30 MG Oral Tablet
Term type
SY
Status
DailyMed mapping
Updated
2026-06-04 23:39:07

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
PALSONIFYPALTUSOTINECrinetics Pharmaceuticals, Inc.8a6d2ce0-a621-4ee7-983c-977cd948ff4d2025-09-16Warnings, Adverse reactionsExact identifier
rxcui: 2724413

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
8a6d2ce0-a621-4ee7-983c-977cd948ff4dPalsonify 30 MG Oral Tablet, Once Daily [PSN] · paltusotine 30 MG Oral Tablet [Palsonify] [SBD] · Palsonify 30 MG (equivalent to paltusotine hydrochloride 32.4 MG) Oral Tablet [SY] · Palsonify 30 MG Oral Tablet [SY]43These highlights do not include all the information needed to use PALSONIFY™ safely and effectively. See full prescribing information for PALSONIFY. PALSONIFY (paltusotine) tablets, for oral use Initial U.S. Approval: 202520250916